MARKET

NBIX

NBIX

Neurocrine Biosciences Inc
NASDAQ
120.00
+0.53
+0.44%
After Hours: 120.00 0 0.00% 16:20 12/07 EST
OPEN
119.47
PREV CLOSE
119.47
HIGH
121.33
LOW
118.62
VOLUME
876.34K
TURNOVER
0
52 WEEK HIGH
125.02
52 WEEK LOW
89.04
MARKET CAP
11.79B
P/E (TTM)
64.17
1D
5D
1M
3M
1Y
5Y
Neurocrine Biosciences Inc: Report of proposed sale of securities
Press release · 1d ago
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and CVS Health (CVS)
Neurocrine (nbix) and cvs health (cvs) have received a lot of coverage today. Rbc capital analyst brian abrahams maintained a hold rating on neurocrine. Cvs health analyst ben hendrix reiterated a buy rating on the company.
TipRanks · 1d ago
Health Care Sector Update for 12/06/2023: PHVS, PHR, NBIX, XLV, IBB
NASDAQ · 1d ago
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Crinetics Pharmaceuticals (CRNX) and IGM Biosciences (IGMS)
Neurocrine, crinetics pharmaceuticals and igm biosciences have received a lot of coverage today. Piper sandler reiterated a hold rating on neurocrine and maintained a buy rating on igm. Piper's david amsellem also reiterated a buy rating on the healthcare sector company.
TipRanks · 1d ago
Neurocrine Biosciences: A Balancing Act Between Diversification Strategy and Pipeline Risks
TipRanks · 1d ago
Hold Rating on Neurocrine Biosciences Amid Promising Pipeline and Development Timelines
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Phreesia (PHR) and Neurocrine (NBIX)
TipRanks · 1d ago
Buy Rating Affirmed for Neurocrine Biosciences Amid Strong R&D and Strategic Growth Prospects
TipRanks · 1d ago
More
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).

Webull offers Neurocrine Biosciences, Inc. stock information, including NASDAQ: NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.